Investigation of Analgesic Effects of Venlafaxine, Atomoxetine and Trazodone Alone and in Combination in Acute Pain Models of the Rats
-
Published:2022-09-19
Issue:
Volume:
Page:
-
ISSN:2717-7173
-
Container-title:Turkish Journal of Science and Health
-
language:en
-
Short-container-title:TFSD
Author:
KEMERLİ Münteha Zeynep1, YILDIRIM Kemal1, JOHA Zıad2, TAŞKIRAN Ahmet Şevki1, BAĞCİVAN İhsan1
Affiliation:
1. SIVAS CUMHURIYET UNIVERSITY 2. cumhuriyet university
Abstract
Purpose: Poorly controlled pain is linked to several other undesirable outcomes. These outcomes are upsetting to patients, their families, and society as a whole. Although opioids and non-steroidal anti-inflammatory drugs are the cornerstone of the nociceptive pain treatment, the use of these drugs is restricted due to their side effects. Therefore, it is essential to develop new treatment alternatives for pain. Our study aimed to examine the pain relief effectiveness of Venlafaxine, Atomoxetine and Trazodone at 3 different doses alone, and in combination with each other in an acute pain model.
Material and Methods: The analgesic effectiveness of Venlafaxine, Atomoxetine, and Trazodone at three different doses alone and in combination in an acute pain model in rats was examined using the hot plate and tail flick methods.
Results: Venlafaxine and Trazodone, Venlafaxine showed dose-dependent analgesic effect when compared to the control. When Venlafaxine at dose of 2 mg/kg were combined with Atomoxetine at doses of 1, 3 and 6 mg/kg, the analgesic effects were significantly increased compared to these drugs alone. When Venlafaxine at dose of 2 mg/kg were combined with trazodone at doses of 4, 12 and 24 mg/kg, the analgesic effects were significantly increased compared to these drugs alone.
Conclusion: All in all, our data suggest these combinations may offer a beneficial treatment option for acute pain in future.
Publisher
Turk Fen Ve Saglik Dergisi
Subject
Industrial and Manufacturing Engineering,Polymers and Plastics,Business and International Management
Reference27 articles.
1. Barbaros, M.B., Can, Ö.D., Üçel, U.I., Yücel, N.T., DemirÖzkay, Ü., 2018. Antihyperalgesic Activity of Atomoxetine on Diabetes-Induced Neuropathic Pain: Contribution of Noradrenergic and Dopaminergic Systems. Mol. 2018, Vol. 23, Page 2072 23, 2072. https://doi.org/10.3390/MOLECULES23082072 2. Bonnefont, J., Chapuy, E., Clottes, E., Alloui, A., Eschalier, A., 2005. Spinal 5-HT1A receptors differentially influence nociceptive processing according to the nature of the noxious stimulus in rats: effect of WAY-100635 on the antinociceptive activities of paracetamol, venlafaxine and 5-HT. Pain 114, 482–490. https://doi.org/10.1016/J.PAIN.2005.01.019 3. Cegielska-Perun, K., Bujalska-Zadrozny, M., Makulska-Nowak, H.E., 2012. Modification of morphine analgesia by venlafaxine in diabetic neuropathic pain model. Pharmacol. Reports 64, 1267–1275. https://doi.org/10.1016/S1734-1140(12)70923-4 4. Chen, J. (Steven), Kandle, P.F., Murray, I., Fitzgerald, L.A., Sehdev, J.S., 2021. Physiology, Pain. StatPearls. 5. Cortes-Altamirano, J.L., Olmos-Hernandez, A., Jaime, H.B., Carrillo-Mora, P., Bandala, C., Reyes-Long, S., Alfaro-Rodríguez, A., 2018. Review: 5-HT1, 5-HT2, 5-HT3 and 5-HT7 Receptors and their Role in the Modulation of Pain Response in the Central Nervous System. Curr. Neuropharmacol. 16. https://doi.org/10.2174/1570159X15666170911121027
|
|